Overview

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Status:
Recruiting

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Accelerating Medicines Partnership (AMP)
Alzheimer's Association
Eisai Inc.
National Institute on Aging (NIA)